Use of VEGF antagonists for the treatment of malignant gliomas
US7354582B2 · kind B2 · utility
11Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2006 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Apr 23, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.